A Phase III, Randomized, Double-blind Study to Assess the Consistency of the Immunogenicity of Three Consecutive Production Lots of Bivalent HPV Vaccine in Healthy Female Subjects Aged 9 - 30 Years and to Demonstrate Non-inferiority of the Candidate HPV Vaccine Manufactured at Commercial Scale Compared With a Pilot Scale

Shanghai Zerun Biotechnology Co.,Ltd1 site in 1 country1,100 target enrollmentApril 20, 2021

ConditionsHPV Infection

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: HPV Infection
Sponsor: Shanghai Zerun Biotechnology Co.,Ltd
Enrollment: 1100
Locations: 1
Primary Endpoint: Percentage of participants who seroconvert to HPV-16 and/or HPV-18 at one month post 3rd dose
Status: Completed
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to evaluate the immunogenicity and safety of three consecutive lots of bivalent HPV (Type 16,18) vaccine (Pichia pastoris) in healthy female subjects aged 9 - 30 years, and demonstrate the non-inferiority of the candidate HPV vaccine manufactured at commercial scale compared with a pilot scale.

Registry

clinicaltrials.gov

Start Date

April 20, 2021

End Date

May 16, 2022

Last Updated

3 years ago

Study Type

Interventional

Study Design

Parallel

Sex

Female

Investigators

Sponsor

Shanghai Zerun Biotechnology Co.,Ltd

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•9-30 healthy female able to provide legal identification.
•Written informed consent had to be obtained from the subject prior to enrolment (for subjects below the legal age of consent, written informed consent had to be obtained from a parent or legal guardian of the subject and, in addition, the subject had to sign and personally date a written informed assent).
•Women of child-bearing age(WOCBA): Subject had to have a negative urine pregnancy test, no plan to be pregnant in 7 months, and agree to use adequate contraceptive precautions during study period.

Exclusion Criteria

•Subject has received a marketed HPV vaccine or participated in an HPV vaccine clinical trial.
•History of abnormal cervical screen test result (ASC-US or worse) or history of genital warts.
•History of severe allergic reaction that required medical intervention.
•History of allergic disease or reactions likely to be exacerbated by any component of the study vaccines.
•Pregnant or breastfeeding, or within 6 weeks after the end of pregnancy.
•Fever prior to vaccination (auxiliary temperature ≥37.3 °C).
•Hypertension (physical examination systolic blood pressure 140mmHg and or diastolic blood pressure 90mmHg.
•Received live attenuated vaccine within 15 days before vaccination or subunit or inactivated vaccine within 7 days.
•Received immunoglobulin and/or blood product 3 months prior to the first vaccination.
•Acute diseases or acute stage of the chronic diseases within 3 days preceding the vaccination.

Outcomes

Primary Outcomes

Percentage of participants who seroconvert to HPV-16 and/or HPV-18 at one month post 3rd dose

Time Frame: At Month 7

Seroconversion was defined as: For initially seronegative subjects \[antibody titer below (\<) 1:40 prior to vaccination\], antibody titer greater than or equal to (≥) 1:40 after vaccination; For initially seropositive subjects (antibody titer ≥ 1:40 prior to vaccination), antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer.

Geometric Mean Titers (GMTs) for HPV-16 and/or HPV-18 at one month post 3rd dose

Time Frame: At Month 7

Secondary Outcomes

Incidence of solicited adverse events (AEs) after vaccination(0~7 days after each vaccination)
Incidence of unsolicited AEs after vaccination(0~30 days after each vaccination)
Incidence of serious adverse events (SAEs)(Month 0 to Month 7)
Incidence of Treatment-Emergent Adverse Events (TEAE) during 30 days after each dose(0~30 days after each vaccination)